Ustekinumab for moderately to severely active Crohn’s disease after previous treatment

  • Technology appraisal guidance
  • TA456
  • Published: 
Download guidance (PDF)

3 Evidence

The appraisal committee considered evidence submitted by Janssen and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.